Prime Therapeutics

Did you know that 80% of the drugs and supplemental indications currently awaiting FDA decisions are specialty products? And nearly half have an orphan drug designation, underscoring the continued focus on rare and complex conditions. The July 2026 Quarterly Drug Pipeline examines the therapies, regulatory milestones and market developments that could shape future pharmacy and medical benefit strategies. See what’s ahead and start planning for what it could mean for your organization: https://ctrly.io/vsLnD #SpecialtyPharmacy #DrugPipeline #HealthPlans

The hottest questions in specialty won’t answer themselves. Join the leaders ready to tackle specialty’s biggest challenges at the 2026 #SpecialtySummit. From pipeline and policy to AI, medical pharmacy and the future of care, this is where timely perspectives turn into conversations that move the industry forward.  Register now: https://ctrly.io/MNUfc

Through servant leadership and a people-first approach, Greg Mastroianni stays focused on our purpose. See what advice Greg would share with his younger self and learn more about his life in and outside of work.

New approvals are only part of the drug pipeline story. Through Q2 2026, the FDA approved new therapies and expanded indications across specialty, oncology, traditional drugs, biosimilars, vaccines and cell and gene therapies. Share your perspective, then explore our quarterly FDA approvals update for a closer look at the developments shaping the 2026 drug landscape: https://ctrly.io/QeYAI

Several FDA decisions are anticipated in August and September across oncology, neurology, metabolic conditions and other therapeutic areas — including potential gene therapies. See what these developments could mean for health plans and the people they serve. Explore the July 2026 Quarterly Drug Pipeline to see what’s approaching and the considerations to keep on your radar. Read the latest report: https://ctrly.io/vsLnD #DrugPipeline #ManagedCare #PharmacyBenefits

Policy is shifting fast. Are you caught up? New industry and policy updates are already influencing how plans think about contracting and operations. Dive into the 2026 Summer Prime Therapeutics Report’s newsstand section to see what changed, what it means and what to watch next.    👉 Get the key takeaways: https://ctrly.io/LiElj

Where CAR-T therapy is delivered is beginning to change, and that shift brings new considerations for managed care. Read the full article: https://ctrly.io/PQxeT #Oncology #CARTCellTherapy #ManagedCare #SiteOfCare

The conversations shaping specialty care are happening at #SpecialtySummit 2026. From drug pipeline trends and payer strategies to AI, oncology, and cell and gene therapy, this year's agenda is focused on what’s next and what it means for pharmacy leaders today.    Swipe through for a preview of key sessions. Then secure your spot in Washington, D.C., Sept. 21–23. Register now and learn more at: https://ctrly.io/MNUfc

What makes Prime Therapeutics different than other PBMs? Owned by 19 nonprofit Blue Cross Blue Shield plans, we always put people first and deliver innovative solutions built around what matters most. Watch this video to learn what George Van Antwerp, senior vice president, product innovation, thinks makes Prime stand out.

115 FDA developments. One rapidly evolving drug landscape. Through Q2 2026, new drug approvals and expanded indications continued across specialty, oncology, traditional therapies, biosimilars, vaccines and cell and gene therapies. Our latest quarterly update breaks down the activity and developments worth watching as the year progresses. Explore the Q2 update: https://ctrly.io/QeYAI #FDAApprovals #DrugPipeline #HealthcareInnovation